WO2020030091A1 - 用于治疗组织坏死或改善心脏功能的药物 - Google Patents
用于治疗组织坏死或改善心脏功能的药物 Download PDFInfo
- Publication number
- WO2020030091A1 WO2020030091A1 PCT/CN2019/099947 CN2019099947W WO2020030091A1 WO 2020030091 A1 WO2020030091 A1 WO 2020030091A1 CN 2019099947 W CN2019099947 W CN 2019099947W WO 2020030091 A1 WO2020030091 A1 WO 2020030091A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- days
- eggs
- amniotic fluid
- age
- pharmaceutical composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
Definitions
- the present invention relates to a therapeutic drug for treating tissue necrosis or improving cardiac function.
- hypoxia due to ischemia results in the local tissue and cell metabolism to stop and its functions completely lost.
- Cells can die by changes in nuclear enrichment, nuclear fragmentation, and lysis, resulting in tissue necrosis.
- Myocardial infarction is one of the examples of tissue necrosis caused by ischemia and hypoxia. It refers to the interruption of coronary blood on the basis of coronary artery disease, which causes the corresponding myocardium to develop severe and persistent acute ischemia, eventually leading to acute, persistent Myocardial necrosis caused by ischemia and hypoxia (coronary insufficiency).
- Patients with acute myocardial infarction often have persistent severe sternum pain, fever, increased white blood cell count, elevated serum myocardial enzymes, and electrocardiograms that reflect a series of characteristic evolutions of acute myocardial injury, ischemia, and necrosis.
- the occurrence of arrhythmia, shock, and heart failure is a serious type of coronary heart disease. It can be complicated by arrhythmia, shock, or heart failure and is often life-threatening.
- the invention provides a pharmaceutical composition, the pharmaceutical composition contains:
- Amniotic fluid and / or its extracts from non-human animals and
- An optional pharmaceutically acceptable carrier is an optional pharmaceutically acceptable carrier
- the amniotic fluid is derived from eggs with an embryo age of 5-12 days, preferably eggs with an embryo age of 6-11 days, more preferably eggs with an embryo age of 7-9 days, and more preferably eggs with an embryo age of 7-8 days Or eggs from avians other than chickens at a developmental stage corresponding to the developmental period of the embryonic age eggs; or embryos from rodents with a gestational age of 8-20 days, preferably 8-14 days, Or embryos from non-human mammals other than rodents whose developmental period corresponds to the developmental period of rodents with a gestational age of 8-20 days, preferably 8-14 days.
- the pharmaceutical composition is a cryopreserved amniotic fluid and / or an extract thereof, or a lyophilized reagent of the amniotic fluid and / or an extract thereof.
- the pharmaceutical composition is an infusion solution.
- the pharmaceutical composition does not contain or contain isotonic saline, water for injection or glucose injection.
- the eggs of the other birds are birds with an embryonic age of 5-20 days.
- the eggs of the other birds are eggs with an embryo age of 6-15 days.
- the amniotic fluid is derived from eggs with an embryonic age of 7 days.
- the eggs of the other birds are duck eggs, goose eggs, or a combination thereof.
- the invention also provides the use of amniotic fluid and / or its extract in the preparation of a medicament for treating tissue necrosis caused by ischemia and hypoxia, wherein the amniotic fluid is derived from eggs with an embryonic age of 5-12 days, and preferably with an embryonic age of 6 -11 days of eggs, more preferably 7-9 days of eggs, more preferably 7-8 days of eggs, or chickens from a development period corresponding to the development period in which the eggs of the embryo age Eggs from birds other than birds; or embryos from rodents with gestational age of 8-20 days, preferably 8-14 days, or from rodents with developmental and gestational ages of 8-20 days, preferably 8-14 days
- the animal's developmental stage corresponds to embryos of non-human mammals other than rodents.
- the tissue necrosis is myocardial ischemic necrosis.
- the tissue necrosis is a myocardial infarction.
- the eggs of the other birds are birds with an embryonic age of 5-20 days.
- the eggs of the other birds are eggs with an embryo age of 6-15 days.
- the amniotic fluid is derived from eggs with an embryonic age of 7 days.
- the eggs of the other birds are duck eggs, goose eggs, or a combination thereof.
- the invention also provides the use of amniotic fluid and / or its extract in the preparation of a medicament for improving cardiac function, wherein the amniotic fluid is derived from eggs with an embryonic age of 5-12 days, preferably eggs with an embryonic age of 6-11 days, more Eggs with an embryonic age of 7-9 days, more preferably eggs with an embryonic age of 7-8 days, or eggs from birds other than chickens whose developmental period corresponds to the developmental period in which the embryonic-aged eggs are located; Or from embryos of rodents with a gestational age of 8-20 days, preferably 8-14 days, or from developmental stages corresponding to the developmental period of rodents with a gestational age of 8-20 days, preferably 8-14 days Embryos of non-human mammals other than rodents.
- the eggs of the other birds are birds with an embryonic age of 5-20 days.
- the eggs of the other birds are eggs with an embryo age of 6-15 days.
- the amniotic fluid is derived from eggs with an embryonic age of 7 days.
- the eggs of the other birds are duck eggs, goose eggs, or a combination thereof.
- the medicament is used to improve heart failure, especially senile heart failure or heart failure.
- the present invention also provides a method for treating tissue necrosis caused by ischemia and hypoxia, which method comprises administering a therapeutically effective amount of amniotic fluid and / or an extract thereof to a subject in need, wherein the amniotic fluid comes from an embryonic age of 5- 12-day eggs, preferably eggs with an embryo age of 6-11 days, more preferably eggs with an embryo age of 7-9 days, more preferably eggs with an embryo age of 7-8 days, or Eggs of other birds other than chickens corresponding to the developmental period of the eggs; or embryos from rodents with a gestational age of 8-20 days, preferably 8-14 days, or from the developmental period and gestational age of 8-20 Embryos of non-human mammals other than rodents corresponding to the developmental period of the rodents, preferably 8-14 days.
- the method includes intravenously injecting a pharmaceutical formulation containing the amniotic fluid and / or its extract, or infusion of a pharmaceutical formulation containing the amniotic fluid and / or its extract.
- the eggs of the other birds are birds with an embryonic age of 5-20 days.
- the eggs of the other birds are eggs with an embryo age of 6-15 days.
- the amniotic fluid is derived from eggs with an embryonic age of 7 days.
- the eggs of the other birds are duck eggs, goose eggs, or a combination thereof.
- the present invention also provides a method for improving cardiac function, the method comprising administering to a subject in need thereof a therapeutically effective amount of amniotic fluid and / or an extract thereof, wherein the amniotic fluid is derived from eggs with an embryo age of 5-12 days, preferably embryos.
- mice 6-11 days old eggs, more preferably 7-9 days old eggs, more preferably 7-8 days old eggs, or derived from a developmental period that is in phase with the developmental period in which the eggs are located
- Eggs from other birds other than chickens or embryos from rodents with gestational age of 8-20 days, preferably 8-14 days, or from developmental stage and gestational age of 8-20 days, preferably 8-14 days
- the developmental stages of rodents correspond to embryos of non-human mammals other than rodents.
- the method includes intravenously injecting a pharmaceutical formulation containing the amniotic fluid and / or its extract, or infusion of a pharmaceutical formulation containing the amniotic fluid and / or its extract.
- the eggs of the other birds are birds with an embryonic age of 5-20 days.
- the eggs of the other birds are eggs with an embryo age of 6-15 days.
- the amniotic fluid is derived from eggs with an embryonic age of 7 days.
- the eggs of the other birds are duck eggs, goose eggs, or a combination thereof.
- the method for improving cardiac function is a method for improving heart failure, especially a method for improving senile cardiac hypofunction or cardiac insufficiency.
- FIG. 1 Ejection fraction of myocardial infarction mice. Cardiac ultrasound can measure the ejection fraction and left ventricular short axis shortening rate in mice. It can be seen from the figure that the treatment of amniotic fluid (EE) significantly increased the ejection fraction of myocardial infarction mice and significantly improved cardiac function.
- EE amniotic fluid
- FIG. 2 Left ventricular short-axis shortening rate in myocardial infarction mice. Cardiac ultrasound can measure the ejection fraction and left ventricular short axis shortening rate in mice. It can be seen from the figure that the treatment of amniotic fluid (EE) significantly increased the left ventricular short axis shortening rate of myocardial infarction mice and significantly improved cardiac function.
- EE amniotic fluid
- FIG. 3 Masson trichrome staining of myocardial infarcted mouse hearts. It can be seen from the figure that myocardial infarction mice have severe fibrosis and the left ventricular wall is significantly thinner. After treatment with amniotic fluid (EE), the left ventricular wall became thinner and fibrosis was significantly reduced.
- EE amniotic fluid
- FIG. 4 Immunofluorescence staining (PH3, cTnT, DAPI) of the heart of myocardial infarction mice.
- FIG. 5 Immunofluorescence staining of hearts of myocardial infarcted mice (AuroraB, cTnT, DAPI). It can be seen from the figure that the PH3 positive and AuroraB positive cells in the heart of the mice in the treatment group increased significantly, indicating that EE treatment significantly induced heart cell regeneration in myocardial infarction mice.
- FIG. 6 The area of cardiac fibrosis in mice with myocardial infarction was significantly reduced after treatment with amniotic fluid (EE) than in the untreated group (NS).
- EE amniotic fluid
- Figure 7 HPLC results of amniotic fluid of eggs at 7 days of age.
- Figure 8 HPLC results of amniotic fluid of eggs at 11 days of age.
- Figure 9 HPLC results of amniotic fluid of eggs at 13 days of age.
- Figure 10 Free radical resistance of amniotic fluid of eggs of different embryo ages.
- the abscissa indicates the embryonic age, and the ordinate indicates the clearance rate.
- Figure 11 Growth curves of chicken embryo fibroblasts under different culture conditions. Amniotic fluid of eggs can promote cell growth.
- Figure 12 Effect of amniotic fluid from eggs on the growth viability and migration capacity of human umbilical vein endothelial cells (HUVEC).
- the abscissa indicates the culture medium, and the ordinate indicates the OD450 value.
- Figure 13 The effect of amniotic fluid from duck eggs on the growth viability and migration capacity of chicken embryo fibroblasts.
- the abscissa indicates the culture medium, and the ordinate indicates the OD450 value.
- Figure 14 Gel column GE HiLoad 16/600 Superdex 75pg separation chromatogram.
- Figure 15 Cell viability detection gel column GE HiLoad 16/600 Superdex 75pg fractions.
- the abscissa indicates the culture medium, where FBS indicates fetal calf serum; DMEM is Dulbecco's Modified Eagle Medium; EE indicates amniotic fluid; "EE” indicates lyophilized amniotic fluid; S-200B indicates the fraction of the B peak; Q UNBOUND indicates the unbound fraction of the anion column ; 3-1 to 3-6 represent the third step purification of medium volume fractions 1-6, respectively.
- Figure 16 Unbound fractions separated by cell viability detection cation exchange column GE HiPrep SP and anion exchange column HiPrep Q.
- the abscissa indicates the culture medium, where FBS indicates fetal calf serum; DMEM is Dulbecco's Modified Eagle Medium; EE indicates amniotic fluid; "EE” indicates lyophilized amniotic fluid; Hiprep SP-UN indicates fractions that do not bind Hiprep SP column; Hiprep Q-UN Denotes the fraction not bound to the Hiprep Q column; Hiprep Q-Bound represents the fraction bound to the Hiprep Q column.
- Figure 17 Amniotic fluid from eggs promotes the growth of primary cardiomyocytes. Among them, the abscissa indicates the culture medium, and the ordinate indicates the OD450 value.
- Figure 18 EE improves cardiac function and reduces left ventricular remodeling in MI pigs.
- FIG. 19 EE reduces myocardial infarct size and prolongs activity time in IR pigs.
- Figure 20 The effect of amniotic fluid from mice on the growth viability of AC16 cells.
- amniotic fluid and / or its extracts are collectively referred to herein as EE.
- amniotic fluid can come from poultry eggs and non-human mammals.
- Poultry eggs refer to the eggs of birds.
- Preferred birds are poultry such as chicken, duck and goose.
- the present invention uses poultry eggs with an embryo age of 5-20 days, preferably 6-15 days. It should be understood that the appropriate embryo age may not be the same for different poultry eggs. For example, when eggs are used, eggs with an embryonic age of 5-12 days are preferred, eggs with an embryonic age of 6-11 days are more preferred, eggs with an embryonic age of 7-9 days are more preferred, and embryonic age is more preferred. Eggs for 7-8 days.
- eggs whose development period corresponds to the development period of the above-mentioned embryonic age eggs may be used.
- duck eggs with an embryo age of 8-10 days, especially 8-9 days, may be the best.
- Poultry eggs and amniotic fluid can be obtained by conventional methods.
- the blunt end of an egg of the corresponding embryo age can be tapped to break the egg shell and peel the egg shell to form a mouth with a diameter of about 2 cm.
- the amniotic membrane and the associated tissues surrounding the embryo are poured from the shell into a petri dish, and the amniotic fluid is drawn through the amniotic membrane with a syringe until the amniotic membrane is close to the embryo, thereby obtaining the amniotic fluid used in the present invention.
- amniotic fluid can also come from non-human mammals, especially rodents, such as from mice.
- Other non-human mammals can be common domestic animals, such as cattle, sheep, dogs, cats, pigs, and the like.
- the amniotic fluid is derived from an embryo of a rodent having a gestational age of 8-20 days, preferably 8-14 days or 11-16 days, and more preferably 13-14 days, or from a period of development and gestational age that is An embryo of a non-human mammal corresponding to the developmental period of the rodent at 8-20 days, preferably 8-14 days or 11-16 days, more preferably 13-14 days.
- Amniotic fluid can be obtained by conventional methods.
- amniotic fluid used in the present invention can be obtained.
- amniotic fluid may be centrifuged to separate impurities that may be contained, such as egg yolk, etc., to obtain pure amniotic fluid as much as possible.
- the supernatant obtained after centrifugation is the amniotic fluid used in the present invention.
- amniotic fluid as used herein shall mean "pure” amniotic fluid, that is, isolated from avian eggs or non-human mammalian embryos that do not contain Amniotic fluid of other components in bird eggs or non-human mammal embryos, and not contaminated with foreign substances. Pure amniotic fluid can be stored in a refrigerator below -60 ° C and thawed before use.
- the invention uses extracts of amniotic fluid.
- the extract does not bind to the ion exchange column between pH 5.8 and 8.0, and the molecular weight of the contained component is in the range of 500 to 1200 Daltons.
- the neutral fraction having a molecular weight of 500 to 1200 Daltons can be separated from the amniotic fluid, thereby obtaining the extract.
- the methods herein can be performed using gel columns and ion exchange columns well known in the art.
- a well-known gel chromatography column (such as the various gel chromatography columns described below) can be used to separate a molecular weight of 500-1200 Daltons from amniotic fluid, and then use an ion exchange method (such as the following using The ion exchange column) separates the neutral fraction from the fraction.
- the neutral fraction can be separated from the amniotic fluid by ion exchange (such as using an ion exchange column described below) before using a gel chromatography column (such as various gel chromatography columns described below). ) The fraction with a molecular weight in the range of 500-1200 Daltons in the neutral fraction is separated.
- a neutral fraction having a molecular weight of 500-2000 Daltons may be separated from the amniotic fluid first, and then a fraction having a molecular weight in the range of 500-1200 Daltons may be separated therefrom.
- the method may include the following steps:
- a neutral fraction having a molecular weight of 500-1200 Daltons is separated from the neutral fraction having a molecular weight of 500-2000 Daltons.
- Step (1) can be achieved by using gel chromatography and ion exchange methods. Components with a molecular weight of 500-2000 Daltons in amniotic fluid were separated by a gel chromatography column, and an uncharged (neutral) fraction was obtained by ion exchange.
- gel chromatography columns can be used to perform gel chromatography.
- Such gel chromatography columns include, but are not limited to, GE's SephacrylS-100, SephacrylS-200, SephacrylS-300, Sephacryl S -400, Superose 12, Superose 6, Superdex 12, and Superdex 6. It should be understood that any other gel chromatography packing with a separation range of 500-10,000 Daltons can also be used.
- the gel chromatography column can be first equilibrated with ddH 2 O, and the flow rate can be determined according to the actual situation.
- the flow rate may be 0.5-50 ml / min, such as 1 ml / min.
- UV absorption is between 200-300 nm, such as 280 nm. After the UV absorption curve is stable and the baseline is returned, the equilibrium is ended. After equilibration is complete, the sample can be loaded. The loading flow rate is determined according to the actual preparation. After loading, the crude product can be eluted with degassed ddH 2 O, and fractions with molecular weights between 500 and 2000 Daltons are collected. If necessary, the gel chromatography separation can be repeated several times, and the fractions with the same peak time at each separation can be mixed.
- anion exchange and cation exchange can be used in the method of the invention.
- anion exchange methods are used herein.
- Commercially available anion exchange columns can be used, including, but not limited to, DEAE Sepharose, ANX Sepharose, Q Sepharose, Capto DEAE, Capto Q, Mono Q, and Mini Q from GE. It should be understood that other brands of anion exchange packings can also be used.
- commercially available cation exchange columns can also be used, including but not limited to CM Sepharose, SP Sepharose, CaptoS, MonoS, and MiniS.
- the ion exchange column is first equilibrated with a buffer when performing ion exchange.
- the buffer may be a conventional buffer in the art, for example, a phosphate buffer, especially a sodium phosphate buffer may be used.
- the pH of the buffer can be determined based on the ion exchange column used. For example, when an anion exchange column is used, the anion exchange column can be equilibrated with a buffer having a pH of 7.5 to 8.5, preferably 7.5 to 8.0; when a cation exchange column is used, the buffer can be equilibrated with a pH of 5.8 to 7.0, preferably 5.8 to 6.5. Cation exchange column.
- the sodium phosphate buffer contains Na 2 HPO 4 and NaH 2 PO 4 at a pH of about 5.8 or 8.0.
- the present invention preferably uses an anion exchange column for separation.
- the flow rate can be determined according to the actual situation.
- the flow rate may be 0.5-50 ml / min, such as 1 ml / min.
- the ultraviolet absorption curve at 280 nm is stable, and the equilibrium is ended after returning to the baseline.
- step (1) gel chromatography may be performed first to separate a fraction having a molecular weight of 500-2000 Daltons, and then ion exchange may be performed to separate a neutral fraction; or, ion exchange may be performed first to separate out
- the neutral fraction of amniotic fluid is then separated by gel chromatography to separate the active ingredients with molecular weights in the range of 500-2000 Daltons to obtain neutral fractions with molecular weights between 500-2000 Daltons. .
- the main purpose in step (2) is to further separate the neutral fraction obtained in step (1) to obtain an active ingredient with a molecular weight in the range of 500-1200 Daltons.
- a commercially available gel chromatography column can be used to separate fractions having a molecular weight in the range of 500-1200 Daltons.
- Suitable gel chromatography columns include, but are not limited to, HiLoad Superdex 16/600, Superdex 75pg, Superdex Peptide, Superdex 200, and Superdex 30 from GE. It should be understood that other brands of gel chromatography packings with a separation range of 500-10,000 Daltons can also be used.
- the gel column can be equilibrated with ddH 2 O first, and the flow rate can be determined according to the actual situation.
- the flow rate may be 0.5-50 ml / min, such as 1 ml / min.
- the ultraviolet absorption curve at 280 nm is stable, and the equilibrium is ended after returning to the baseline.
- the sample can be loaded. The loading flow rate is determined according to the actual preparation.
- the crude product can be eluted with degassed ddH 2 O, and the fractions are collected to obtain fractions with molecular weights ranging from 500 to 1200 Daltons, which are the extracts described herein.
- the extract obtained by the above method is formulated into a solution with a pH of 5.8-8.0 and passed through a variety of ion exchange columns (including DEAE Sepharose, Q Sepharose, Mono Q, CM Sepharose, SP Sepharose, and Mono S). No active ingredients are bound to these ion exchange columns.
- amniotic fluid and its extracts can promote cell growth (including but not limited to promoting heart cell regeneration after myocardial infarction, such as cardiomyocytes), and improve or improve heart function.
- tissue may be various tissues of the human or animal body, including but not limited to cartilage tissue, meniscus tissue, ligament tissue, tendon tissue, intervertebral disc tissue, periodontal tissue, skin tissue, vascular tissue, muscle tissue, fascial tissue, periosteum Any one or more of tissue, eye tissue, pericardial tissue, lung tissue, synovial tissue, neural tissue, kidney tissue, bone marrow, urogenital tissue, intestinal tissue, liver tissue, pancreatic tissue, spleen tissue and adipose tissue organization.
- the tissue necrosis due to ischemia and hypoxia is myocardial ischemic necrosis. In certain embodiments, the tissue necrosis is myocardial necrosis caused by acute, persistent ischemia and hypoxia, ie, myocardial infarction.
- the amniotic fluid and its extracts herein can also be used to improve heart function, especially to improve heart function in patients with heart failure. In certain embodiments, the amniotic fluid and its extracts herein can be used to improve the heart function and the heart function of patients with senile heart failure or heart dysfunction.
- cardiac dysfunction or cardiac insufficiency is due to a variety of reasons leading to a decrease in the contractile function of the myocardium, reducing the forward blood flow of the heart, and causing symptoms of blood stasis in the systemic circulation or pulmonary circulation.
- amniotic fluid and / or its extracts described herein can be used directly for the purposes described herein and administered to a subject in need.
- the method of administration can be parenteral, intravenous or intracardiac.
- a therapeutically effective amount of amniotic fluid and / or its extract can be mixed with an appropriate amount of physiological saline for injection, water for injection or glucose injection and then administered by, for example, intravenous infusion or intracardiac injection .
- the dosage and frequency of administration can be determined by the medical staff according to the specific condition, the age and sex of the patient, and so on.
- a therapeutically effective amount refers to a dose sufficient to ameliorate or in some way reduce the symptoms associated with the disease.
- Such a dose may be administered as a single dose or may be administered according to an effective treatment regimen.
- the dosage may also cure the disease, but it is usually administered to improve the symptoms of the disease. Repeated administration is generally required to achieve the desired improvement in symptoms.
- a dose to be administered to a human it may usually be 1-200 ml / time, and it may be administered by injection daily or weekly.
- the frequency of administration may be once every two days, every three days, every four days, every five days, or every six days, or every half month, or monthly.
- provided herein is a method of treating tissue necrosis caused by ischemia and hypoxia, the method comprising administering to a subject in need thereof a therapeutically effective amount of the amniotic fluid and / or its extract or containing The step of the pharmaceutical composition of amniotic fluid and / or its extract.
- a method of improving cardiac function in a subject comprising administering to a subject in need thereof an effective amount of amniotic fluid and / or extracts thereof or containing said amniotic fluid and / or Steps of extracting a pharmaceutical composition.
- subject generally refers to animals, such as mammals, and especially humans.
- this document provides a method for treating myocardial ischemic necrosis (especially myocardial infarction), and a method for improving heart failure (especially senile heart failure or cardiac insufficiency) in a subject, the method comprising administering treatment to the subject in need
- the avian eggs are as defined herein or as described in any embodiment herein.
- the poultry eggs are poultry eggs, especially poultry eggs having an embryonic age of 5-12 days, more preferably 6-11 days, more preferably 6-9, more preferably 7-8 days, especially It's an egg.
- the amniotic fluid or extract thereof is the amniotic fluid or extract thereof described herein from a rodent from 8-20 days, preferably 8-14 or 11-16 days, more preferably 13-14 days of pregnancy.
- amniotic fluid and / or extracts thereof as described herein for the manufacture of a medicament for the treatment of tissue necrosis caused by ischemia and hypoxia. Also provided are amniotic fluid and / or extracts thereof as described herein for use in the treatment of tissue necrosis caused by ischemia and hypoxia.
- amniotic fluid and / or its extracts in the manufacture of a medicament for improving cardiac function. Also provided are amniotic fluid and / or extracts thereof as described herein for improving cardiac function.
- amniotic fluid and / or extracts thereof as described herein, especially amniotic fluid and / or extracts thereof in poultry eggs, more preferably with an embryonic age of 5-12
- the amniotic fluid and / or its extract of eggs is more preferably 6-11 days, more preferably 6-9 days, more preferably 7-8 days.
- the amniotic fluid or an extract thereof is an amniotic fluid or an extract thereof as described herein from a rodent that is 8-20 days, preferably 8-14 days or 11-16 days, and more preferably 13-14 days pregnant.
- the pharmaceutical composition may be cryopreserved amniotic fluid and / or an extract thereof or a lyophilized reagent thereof, such as lyophilized amniotic fluid and / or an extract thereof.
- the pharmaceutical composition may also contain other pharmaceutically acceptable carriers or excipients, such as physiological saline for injection, water for injection or glucose injection.
- Microcomputer automatic incubator (Zhengda TM ZF880), clean petri dish, 1.0ml syringe (Jiangxi Hongda TM ), 70% alcohol-sterilized forceps, stainless steel sieve, sterile centrifuge tube ( # SCT-50ML-25-S) and low-speed refrigerated centrifuge (Zhongjia KDC-2046).
- amniotic membrane and the associated tissues from the shell into the petri dish, and pierce the amniotic fluid with a syringe to extract the amniotic fluid.
- the bevel of the needle should be facing away from the embryo until the amniotic membrane is close to the embryo, and then the clear, colorless, and foreign body-free Amniotic fluid is poured into a centrifuge tube inside the ice box.
- amniotic fluid extract collected through the test of the Midalta TM 1800 UV spectrophotometer.
- standard operating procedures of the photometer refer to the instruction manual. Qualified ones can be used for mixing and trimming.
- Rabbit anti-human / mouse Aurora B antibody was purchased from Sigma Aldrich, USA; rabbit anti-human / mouse phosphorylated histone H3 polyclonal antibody was purchased from Merck Millipore, Germany; rabbit anti-human / mouse cTnT polyclonal antibody was purchased from Abcam, UK; Alexa Fluor-594 labeled goat anti-rabbit IgG, Alexa Fluor-488 labeled goat anti-rabbit IgG, Alexa Fluor-594 labeled goat anti-mouse IgG, and Alexa Fluor-488 labeled goat anti-mouse IgG were purchased from American Life Technologies Company; DAPI was purchased from American Sigma Aldrich company; goat Serum working fluid was purchased from Wuhan Baoshide Biological Engineering Co., Ltd.
- Trizol was purchased from Invitrogen Corporation; Doxorubicin Hydrochloride was purchased from Shanghai Shenggong Biological Engineering Co., Ltd.
- the experimental animal was a male C57BL / 6J mouse and was purchased from Shanghai Slark Experimental Animal Co., Ltd.
- Leica Dmi8 fluorescence microscope and Leica IM50 image acquisition system were purchased from Leica Company in Germany; the small animal ultrasound diagnostic instrument was purchased from Canada's VisualSonics Company.
- Triton X-100 Triton X-100 stock solution 5ml, 1 ⁇ PBS 995ml.
- the collagen fibers, mucus, and cartilage were blue (such as light green liquor stained green), the cytoplasm, muscle, cellulose, and glial cells were red, and the nuclei were black and blue.
- mice received isoflurane anesthesia in an induction box, the ventilator frequency was 115 beats / min, the respiration ratio was 1: 1, and the tidal volume was 1.5 ml.
- a 20 g indwelling needle plastic tube was intubated through the mouth and trachea, connected to a small animal ventilator, and continuously anesthetized with pure oxygen containing 2.5% isoflurane. Prepare the skin, open the chest between 3-4 ribs, expose the heart, and ligate the left anterior descending branch with a 7-0 prolene thread. You will see the apex turn white, suture the intercostal space, suture the skin, and disinfect. Switch off the anesthetic and continue aeration until the mouse wakes up.
- mice C57BL / 6J male mice were injected with doxorubicin (5mg / kg) once every 7 days for 8 weeks, and a total of four injections would lead to heart failure in mice, which was verified by cardiac ultrasound.
- mice were sacrificed by intraperitoneal injection of 10% chloral hydrate (200 mg / kg), and the heart was removed. Liver and kidney, OCT embedding or paraffin embedding were also taken for 1 week.
- mice Establish a mouse myocardial infarction model by referring to the method described in (4) above.
- the established mouse myocardial infarction model was divided into control group (NS) and chicken embryo amniotic fluid (EE) treatment group (6 animals in each group).
- EE treatment group 100 ⁇ l of the EE prepared in Example 1 was injected through the tail vein every two days. By the 21st day of the third week, a total of 10 injections were made.
- the control group was injected with 100 microliters of physiological saline 10 times in the same manner.
- Left ventricular ejection fraction is a key classic indicator of left ventricular function.
- An increase in left ventricular ejection fraction indicates that cardiac function in mice is improved after myocardial infarction.
- the ejection fraction of the mouse was calculated by echocardiography, and the results are shown in FIG. 1. It can be seen from Figure 1 that by the third week, the treatment of EE significantly increased the left ventricular ejection fraction of myocardial infarction mice, indicating that the treatment of EE significantly improved the cardiac function of mice after myocardial infarction.
- the left ventricular short-axis shortening rate (LVFS) of each group of mice was calculated by echocardiography, and the results are shown in FIG. 2. It can be seen from FIG. 2 that by the third week, the treatment of EE significantly improved the LVFS of myocardial infarction mice, that is, the cardiac function of mice after myocardial infarction.
- Masson's staining is a classic method for judging myocardial infarction and fibrous tissue.
- the mice of each group treated for 21 days were sacrificed, paraffin sections of myocardial tissue were prepared, and stained according to the above point (3), and the results are shown in FIG. 3.
- blue is the infarcted fibrosis tissue and red is the muscle tissue.
- myocardial infarction mice have severe fibrosis, and fibrosis is significantly reduced after EE treatment; suggesting that the treatment of EE prevents small Fibrosis after Myocardial Infarction in Rats
- the size of the left ventricular cavity is the basis for judging the presence or absence of ventricular dilatation after myocardial infarction.
- Ventricular dilatation is an important sign of decreased cardiac function. It can also be seen from FIG. 3 that the ventricular cavity of the myocardial infarction mice in the control group was severely enlarged, but after 3 weeks of EE treatment, the left ventricular cavity of the mice in the treatment group was not significantly enlarged.
- PH3 staining is an indicator for judging cell regeneration in the heart.
- the mice of each group treated for 21 days were sacrificed, frozen sections of myocardial tissue were prepared, and PH3 staining was performed according to the method described in point (1) above, and the results are shown in FIG. 4.
- FIG. 4 cells with positive PH3 staining (green fluorescent dots, indicated by arrows) in the heart tissue of the EE-treated mice significantly increased, indicating that the treatment of EE promoted the regeneration of cells in the heart tissue.
- AuroraB staining is an indicator for judging cell regeneration in the heart.
- AuroraB staining was performed according to the method described in point (1) above, and the results are shown in Figure 5. From Figure 5, it can be clearly seen that AuroraB staining (green fluorescent dots, arrows) cells in the heart tissue of mice treated with EE The significant increase indicates that the treatment of EE promotes the regeneration of cells in cardiac tissue.
- mice heart failure model Refer to the method (5) above to construct a mouse heart failure model.
- the established mouse heart failure model was divided into a control group and a chicken embryo component extract (EE) treatment group (6 animals in each group).
- EE treatment group 100 ⁇ l of the EE prepared in Example 1 was injected through the tail vein every two days. By the 21st day of the third week, a total of 10 injections were made.
- the control group was injected with 100 microliters of physiological saline 10 times in the same manner.
- Left ventricular ejection fraction is a key classic indicator of left ventricular function.
- An increase in left ventricular ejection fraction indicates that cardiac function in mice is improved after heart failure.
- the ejection fraction of the mice was measured by echocardiography, and the results are shown in FIG. 6. It can be seen from Figure 6 that by the third week, the treatment of EE significantly increased the left ventricular ejection fraction of mice with heart failure, indicating that the treatment of EE significantly improved the heart function of mice with heart failure. The area of left ventricular fibrosis was significantly reduced.
- Hitachi Primaide-type high performance liquid chromatography is used to detect the amniotic fluid components of eggs of different embryo ages.
- Test according to the instruction manual of the chromatograph. Among them, the test was first washed with 100% acetonitrile for 30 minutes, and the flow rate time was 0.8 mL / min, and then the water was equilibrated for 30 minutes, and the flow rate was 0.8 mL / min time. Take a 25 ⁇ L sample and eliminate air bubbles. Click the “Data Acquisition” button of the software that comes with the chromatograph, select “Method 2”, and click “Single Analysis Start” at the bottom of the screen. When the system waits for injection, start to inject the sample. The injection should be quick, and the valve should be switched after the injection.
- the method 2 is as follows:
- amniotic fluid with a gestational age of 7 days, 11 days, and 13 days is detected, and the results are shown in Figs. 7-9.
- DPPH 1,1-diphenyl-2-picrylhydrazine radical, and its structure is as follows:
- DPPH a stable free radical, provides an ideal and simple pharmacological model for the detection of free radical scavenging activity.
- DPPH is used to detect the free radical resistance of chicken embryo amniotic fluid.
- Example 1 The method described in Example 1 was used to obtain amniotic fluid of chicken embryos with embryonic ages of 6, 7, 8, 9, 9, and 11 days, and then stored in a refrigerator at 4 ° C for use after centrifugation.
- Vitamin C was used as a positive control to determine the standard curve. Take different volumes of 0.04mg / ml Vc samples and add 0.6ml of DPPH, add absolute ethanol to make up to 1ml, mix well, use methanol as a control to zero, and measure the absorbance at 519nm wavelength. Plot the data after three replicates.
- test group Sample solution 95% ethanol (or anhydrous ethanol) DPPH test solution total capacity Blank group 0mL 0.4mL 0.6mL 1mL Vc n ⁇ L (400-n) ⁇ L 0.6mL 1mL Sample set 0.4mL 0mL 0.6mL 1mL
- Creatine clearance (inhibition rate) from the following companies:
- This example tests the effect of egg amniotic fluid (EE) of Example 1 on the growth of chicken embryo fibroblasts under different culture conditions.
- the composition of the DMEM medium used in this example is as follows: # Cat.11960077, add 1% L-glutamine ( # G0200) and 5% FBS ( # Cat.10099141)), 0.25% trypsin (Hangzhou Keyi Biological TM # CY003), PBS (BI TM # 02-024-1ACS), 0.4% trypan blue stain (BBI TM # 72-57-1) .
- Discard the supernatant add 4 ml of DMEM medium, and resuspend the cells with a pipette tip. Inject 1 ml of the cell suspension into 10 cm cell culture dishes containing 10 ml of fresh medium containing different volume ratios of amniotic fluid. Shake the culture dish in the cross direction, at least 20 times in each direction, to make the cells uniformly distributed, and culture at 37 ° C and 5% CO 2 .
- Figure 11 shows that after 96 hours of incubation, the number of chicken embryo fibroblasts in the experimental group with EE was significantly higher than the number of cells with the control without EE.
- Example 2 The same method as in Example 1 was used to obtain amniotic fluid of duck eggs with an embryonic age of 8 days. Scratch experiments were used to test the effects of egg amniotic fluid on chicken embryo fibroblasts and duck egg amniotic fluid on human umbilical vein endothelial cells (HUVEC) growth viability and migration ability. Duck eggs and amniotic fluid were obtained from duck eggs with an embryonic age of 8 days and obtained by the method of Example 1. Chicken embryo fibroblasts were obtained by the method described in Example 5, and human umbilical vein endothelial cells were obtained from a commercially available route.
- VEC human umbilical vein endothelial cells
- composition of the DMEM medium used in this example is as follows: # Cat.11960077, add 1% L-glutamine ( # G0200) and 5% FBS ( # Cat.10099141)), 0.25% trypsin (Hangzhou Keyi Biological TM # CY003), PBS (BI TM # 02-024-1ACS), 0.4% trypan blue stain (BBI TM # 72-57-1) .
- the width is preferably 1000-2000 ⁇ m. Wash each well 3 times with 2ml PBS and wash away the cells from the scratches. 2ml of medium containing different content of EE was added to each well, and the culture was changed every 48 hours. The timing of the scratch was 0h, and photos were taken at fixed points every 24 hours to measure the cell spacing on both sides of the scratch. Observe the cell growth status in each well; draw a chart with time (days) as the horizontal axis and the scratch distance in each well as the vertical axis; calculate the healing speed of the scratches in each well.
- FIG. 12 shows the effect of amniotic fluid from eggs on the growth viability and migration ability of human umbilical vein endothelial cells (HUVEC). The addition of 5% (volume ratio) amniotic fluid significantly promoted the healing of HUVEC.
- Figure 13 shows the effect of amniotic fluid from duck eggs on the growth viability and migration capacity of chicken embryo fibroblasts. The addition of amniotic fluid also showed a very significant promotion effect on the healing of chicken embryo fibroblasts.
- HUVEC human umbilical vein endothelial cells
- the purpose of this example is to gradually purify the biologically active compounds of chicken embryo amniotic fluid through analytical column gel column SephacrylS-200, anion exchange column HiPrep Q, desalting column HiPrep 26/10 Desalting, HiLoad 16/600 Superdex75pg.
- Step 1 Gel column GE Sephacryl S-200
- Step 2 Anion exchange column GE HiPrep Q
- Sample loading Take the biologically active fraction purified in the first step, use a pump to load the sample at a flow rate of 1.5ml / min, and load 250ml, while collecting the unbound portion of the anion column with an equal volume, 2ml / tube;
- Desalting The bound and unbound fractions in the ion column are replaced with degassed ddH 2 O by GE HiPrep 26/10 Desalting, respectively, and the desalted portion is collected;
- Step 3 Gel column GE HiLoad 16/600 Superdex75pg
- Test cell activity After digesting AC16 with better growth, spread it in 96-well plate, 8000 cells / well, five duplicate wells per group. The cells were adhered in a 5% CO 2 saturated humidity 37 ° C incubator for 2 hours. After 24 hours of starvation in culture with DMEM, it was replaced with 10% FBS DMEM, DMEM, and 20% (volume ratio) added medium. After 24 hours of incubation, 10 ⁇ l of CCK-8 reagent was added to each well. After 2 hours of incubation, absorbance was measured at 450 nm on a microplate reader.
- Step 1 Gel column GE Sephacryl S-200
- Step 2 cation exchange column GE HiPrep SP
- Sodium phosphate buffer A 50mM Na 2 HPO 4 + NaH 2 PO 4 , pH 5.8 equilibrated cation exchange column: flow rate 2ml / min, until the ultraviolet absorption curve at 280nm is stable, and returns to baseline;
- Sample loading Take the fraction with molecular weight in the range of 500-2000 Dalton obtained in the first step, use the pump to load the flow rate of 1.5ml / min, the loading volume is 250ml, and collect the unbound part of the cation exchange column;
- Step 3 Gel column GE HiLoad 16/600 Superdex75pg
- the better-growing AC16 was digested and spread in 96-well plates at 8,000 cells / well, with five replicates in each group.
- the cells were adhered in a 5% CO 2 saturated humidity 37 ° C incubator for 2 hours. After 24 hours of starvation in culture with DMEM, it was replaced with 10% FBS DMEM, DMEM, and 20% (volume ratio) added medium. After 24 hours of incubation, 10 ⁇ l of CCK-8 reagent was added to each well. After 2 hours of incubation, absorbance was measured at 450 nm on a microplate reader.
- the cell viability of the unbound region after cation exchange column GE HiPrep SP treatment is shown in FIG. 16.
- the first step an ion exchange column, an anion exchange column HiPrep Q can be used to make the pH of each solution 5.8 and 8.0, and then load and ion exchange column, flow rate 2ml / min, until the UV absorption curve at 280nm is stable, return to baseline ;
- Sample loading Take amniotic fluid, use the pump to load the flow rate of 1.5ml / min, the loading volume is 50ml, and collect the unbound fraction of the ion column;
- Step 2 Gel column GE Sephacryl S-200
- the sample is the unbound fraction in the first step, the flow rate is 1ml / min, and the loading amount is 10ml;
- Step 3 Gel column GEHiLoad 16/600 Superdex75pg
- Sample loading Take the fractions in the range of 500-2000 Dalton obtained in the second step, and load the sample at a flow rate of 1ml / min and a loading volume of 10ml;
- the better-growing AC16 was digested and spread in 96-well plates at 8,000 cells / well, with five replicates in each group.
- the cells were adhered in a 5% CO 2 saturated humidity 37 ° C incubator for 2 hours. After 24 hours of starvation in culture with DMEM, it was replaced with 10% FBS DMEM, DMEM, and 20% (volume ratio) added medium. After 24 hours of incubation, 10 ⁇ l of CCK-8 reagent was added to each well. After 2 hours of incubation, absorbance was measured at 450 nm on a microplate reader.
- the cell viability of the non-binding region after anion exchange column GE HiPrep Q treatment is shown in FIG. 16.
- the ventricles of the suckling rats were washed with pre-chilled PBS, and then the heart tissue was cut in DMEM / F12. Shake at 37 ° C in a water bath and digest with 0.04% collagenase II + 0.08% trypsin. Filter and centrifuge the digested cells with a sieve, 1000 r / min, 10 min. Add 15% FBS cell culture solution to plate and incubate in a 5% CO 2 saturated humidity 37 ° C incubator.
- Figure 18 shows that chicken EE treatment of myocardial infarction in large white pigs can increase left ventricular ejection fraction and short-axis shortening rate of myocardial infarction in large white pigs.
- Postoperative heart function of large white pigs in the control group showed a gradual decline, while Ventricular function improved to some extent, and EF and FS were significantly higher at 2 weeks, 4 weeks, and 8 weeks than the control group ( Figure 18, A and C).
- ⁇ EF and ⁇ FS statistics were calculated using the difference from the preoperative baseline values. It was found that the EF and FS significantly decreased compared to the preoperative decrease values at 1 week after EE treatment, and the decrease values at 2 weeks, 4 weeks, and 8 weeks in the treatment group were significant.
- EE can significantly increase the left ventricular ejection fraction and stroke volume of ischemia-reperfusion pigs, reduce left ventricular remodeling caused by myocardial infarction, reduce pulmonary congestion in ischemia-reperfusion pigs, and increase Daily activity.
- TTC staining results showed that the area of myocardial infarction in the EE treatment group was significantly lower than that of the control group.
- Tissue Masson staining results showed that the left anterior wall of the large white pigs in the control group had transmural infarction and the fibrotic area was significantly higher than that of the EE treatment group ; Fluorescence staining results show that EE can increase the angiogenesis in the infarcted area of white pigs.
- Example 1 Refer to the method described in Example 1 to obtain amniotic fluid of 13-14 days of gestational age in mice. After equilibrating the centrifuge tube collecting the amniotic fluid extract, use a Zhongjia TM KDC-2046 low-speed refrigerated centrifuge at 5 ° C and 3500 rpm for 21 minutes. (Refer to the manual for the standard operating procedure of the centrifuge). The supernatant was decanted and transferred to a clean plastic storage tank and stored in a -80 ° C refrigerator. Reserve 5ml samples for each batch for subsequent testing. All steps are performed under sterile conditions.
- Test cell activity After digesting AC16 with better growth, spread it in 96-well plate, 8000 cells / well, five duplicate wells per group. The cells were adhered in a 5% CO 2 saturated humidity 37 ° C incubator for 2 hours. After 24 hours of starvation in DMEM, 10% FBS DMEM and DMEM were replaced with 2.5%, 5%, 10%, and 20% (volume ratio) mouse EE medium. After 24 hours of incubation, 10 ⁇ l of CCK-8 reagent was added to each well. After 2 hours of incubation, absorbance was measured at 450 nm on a microplate reader.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
时间(min) | 水(%) | 乙腈(%) | 流量(mL/min) |
0.0 | 100.0 | 0.0 | 0.8 |
11.0 | 100.0 | 0.0 | 0.8 |
17.0 | 95.0 | 5.0 | 0.8 |
30.0 | 90.0 | 10.0 | 0.8 |
45.0 | 55.0 | 45.0 | 0.8 |
60.0 | 0.0 | 100.0 | 0.8 |
70.0 | 0.0 | 100.0 | 0.8 |
实验组 | 样品液 | 95%乙醇(或无水乙醇) | DPPH测试液 | 总体积 |
空白组 | 0mL | 0.4mL | 0.6mL | 1mL |
Vc | nμL | (400-n)μL | 0.6mL | 1mL |
样品组 | 0.4mL | 0mL | 0.6mL | 1mL |
Claims (10)
- 一种药物组合物,其特征在于,所述药物组合物含有:非人动物的羊水和/或其提取物,和任选的药学上可接受的载体;其中,所述羊水来自胚龄为5-12天的鸡蛋,优选胚龄为6-11天的鸡蛋,更优选胚龄为7-9天的鸡蛋,更优选胚龄为7-8天的鸡蛋,或者来自发育时期与所述胚龄的鸡蛋所处的发育时期相对应的鸡以外的其它禽类的蛋;或来自胎龄为8-20天、优选8-14天的啮齿类动物的胚胎,或来自发育时期与胎龄为8-20天、优选8-14天的啮齿类动物的发育时期相对应的啮齿类动物以外的其它非人哺乳动物的胚胎。
- 如权利要求1所述的药物组合物,其特征在于,所述药物组合物为冷冻保存的羊水和/或其提取物,或为该羊水和/或其提取物的冻干试剂。
- 如权利要求1所述的药物组合物,其特征在于,所述药物组合物为输注液。
- 如权利要求3所述的药物组合物,其特征在于,所述药物组合物不含有或含有注射用生理盐水、注射用水或葡萄糖注射液。
- 如权利要求1-4中任一项所述的药物组合物,其特征在于,所述羊水来自鸡蛋、鸭蛋、鹅蛋或其组合;或所述羊水来自怀孕10-14天的啮齿类动物。
- 如权利要求1-5中任一项所述的药物组合物,其特征在于,所述提取物在pH5.8-8.0之间不和离子交换柱结合,且其所含成分的分子量在500-1200道尔顿范围。
- 羊水和/或其提取物在制备治疗缺血和缺氧引起的组织坏死的药物中的应用,或在制备改善心脏功能的药物中的应用;其中,所述羊水来自胚龄为5-12天的鸡蛋,优选胚龄为6-11天的鸡蛋,更优选胚龄为7-9天的鸡蛋,更优选胚龄为7-8天的鸡蛋,或者来自发育时期与所述胚龄的鸡蛋所处的发育时期相对应的鸡以外的其它禽类的蛋;或来自胎 龄为8-20天、优选8-14天的啮齿类动物的胚胎,或来自发育时期与胎龄为8-20天、优选8-14天的啮齿类动物的发育时期相对应的啮齿类动物以外的其它非人哺乳动物的胚胎。
- 如权利要求7所述的应用,其特征在于,所述药物用于治疗心肌缺血坏死,例如心肌梗塞;或所述药物用于改善心力衰竭,如老年性心功能减退或心功能不全。
- 如权利要求7-8中任一项所述的应用,其特征在于,所述羊水来自鸡蛋、鸭蛋、鹅蛋或其组合;或所述羊水来自怀孕10-14天的啮齿类动物。
- 如权利要求7-9中任一项所述的应用,其特征在于,所述提取物在pH5.8-8.0之间不和离子交换柱子结合,且其所含成分的分子量在500-1200道尔顿范围。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021531168A JP2021534235A (ja) | 2018-08-10 | 2019-08-09 | 組織壊死の治療又は心臓機能の改善の医薬 |
US17/267,586 US20210308191A1 (en) | 2018-08-10 | 2019-08-09 | Drug Used for Treating Tissue Necrosis or for Improving Cardiac Function |
KR1020217006661A KR20210044242A (ko) | 2018-08-10 | 2019-08-09 | 조직 괴사 치료 및 심장기능 개선에 사용되는 약물 |
AU2019318661A AU2019318661A1 (en) | 2018-08-10 | 2019-08-09 | Drug used for treating tissue necrosis or for improving cardiac function |
EP19847075.9A EP3834834A4 (en) | 2018-08-10 | 2019-08-09 | MEDICINAL PRODUCTS FOR TISSUE CROSSIS OR IMPROVEMENT OF HEART FUNCTION |
CA3109199A CA3109199A1 (en) | 2018-08-10 | 2019-08-09 | Drug used for treating tissue necrosis or for improving cardiac function |
CN201980053589.2A CN112566646A (zh) | 2018-08-10 | 2019-08-09 | 用于治疗组织坏死或改善心脏功能的药物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810911038.2A CN110812369A (zh) | 2018-08-10 | 2018-08-10 | 用于治疗组织坏死或改善心脏功能的药物 |
CN201810911038.2 | 2018-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020030091A1 true WO2020030091A1 (zh) | 2020-02-13 |
Family
ID=69414003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/099947 WO2020030091A1 (zh) | 2018-08-10 | 2019-08-09 | 用于治疗组织坏死或改善心脏功能的药物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210308191A1 (zh) |
EP (1) | EP3834834A4 (zh) |
JP (1) | JP2021534235A (zh) |
KR (1) | KR20210044242A (zh) |
CN (2) | CN110812369A (zh) |
AU (1) | AU2019318661A1 (zh) |
CA (1) | CA3109199A1 (zh) |
WO (1) | WO2020030091A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116059252A (zh) * | 2021-10-29 | 2023-05-05 | 安徽楚沅生物科技有限公司 | 用于预防或治疗肠炎和肠癌的药物 |
WO2024083176A1 (zh) * | 2022-10-20 | 2024-04-25 | 安徽楚沅生物科技有限公司 | 治疗或预防巨噬细胞介导的疾病的药物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1748713A (zh) * | 2005-09-13 | 2006-03-22 | 陈正跃 | 鸡胚胎素的制备方法 |
CN102438636A (zh) * | 2009-05-20 | 2012-05-02 | 卡迪欧参生物科技有限公司 | 用于治疗心脏疾病的药物组合物 |
CN102908366A (zh) * | 2011-08-02 | 2013-02-06 | 天津泽世德生物医药有限公司 | 一种鸡胚活性成分的制备方法 |
US20140093582A1 (en) * | 2011-08-18 | 2014-04-03 | Golden Pearl Investment LLC | Formulation for treatment of dry mouth and mouth sores |
WO2016111726A1 (en) * | 2014-06-15 | 2016-07-14 | Amnio Technology Llc | Amnion derived therapeutic composition and process of making same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551538B2 (en) * | 2011-08-18 | 2013-10-08 | Golden Pearl Investment LLC | Skin formulation, preparation and uses thereof |
US10894066B2 (en) * | 2014-03-06 | 2021-01-19 | Amnio Technology Llc | Amnion derived therapeutic compositions and methods of use |
-
2018
- 2018-08-10 CN CN201810911038.2A patent/CN110812369A/zh active Pending
-
2019
- 2019-08-09 AU AU2019318661A patent/AU2019318661A1/en active Pending
- 2019-08-09 US US17/267,586 patent/US20210308191A1/en active Pending
- 2019-08-09 JP JP2021531168A patent/JP2021534235A/ja active Pending
- 2019-08-09 WO PCT/CN2019/099947 patent/WO2020030091A1/zh unknown
- 2019-08-09 EP EP19847075.9A patent/EP3834834A4/en active Pending
- 2019-08-09 KR KR1020217006661A patent/KR20210044242A/ko active Search and Examination
- 2019-08-09 CA CA3109199A patent/CA3109199A1/en active Pending
- 2019-08-09 CN CN201980053589.2A patent/CN112566646A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1748713A (zh) * | 2005-09-13 | 2006-03-22 | 陈正跃 | 鸡胚胎素的制备方法 |
CN102438636A (zh) * | 2009-05-20 | 2012-05-02 | 卡迪欧参生物科技有限公司 | 用于治疗心脏疾病的药物组合物 |
CN102908366A (zh) * | 2011-08-02 | 2013-02-06 | 天津泽世德生物医药有限公司 | 一种鸡胚活性成分的制备方法 |
US20140093582A1 (en) * | 2011-08-18 | 2014-04-03 | Golden Pearl Investment LLC | Formulation for treatment of dry mouth and mouth sores |
WO2016111726A1 (en) * | 2014-06-15 | 2016-07-14 | Amnio Technology Llc | Amnion derived therapeutic composition and process of making same |
Non-Patent Citations (3)
Title |
---|
GH H FARJAH: "The effect of chick embryo amniotic fluid on sciatic nerve regeneration of rats", IRANIAN JOURNAL OF VETERINARY RESEARCH, SCHOOL OF VETERINARY MEDICINE, UNIVERSITY OF SHIRAZ, IRAN, 1 January 2015 (2015-01-01), Iran, pages 167 - 171, XP055684078, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827681/pdf/ijvr-16-167.pdf> * |
See also references of EP3834834A4 * |
ZHANG, XIAOHONG ET AL.: "Influences of Eggembryosin on Erythrocyte Quantity and Immune Organ Mass in Mice Abstract", JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING, vol. 11, no. 28, pages 20070715 * |
Also Published As
Publication number | Publication date |
---|---|
CN110812369A (zh) | 2020-02-21 |
JP2021534235A (ja) | 2021-12-09 |
AU2019318661A1 (en) | 2021-03-11 |
CN112566646A (zh) | 2021-03-26 |
EP3834834A1 (en) | 2021-06-16 |
US20210308191A1 (en) | 2021-10-07 |
KR20210044242A (ko) | 2021-04-22 |
CA3109199A1 (en) | 2020-02-13 |
EP3834834A4 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020030097A1 (zh) | 促进细胞生长和组织修复的方法及组合物 | |
CN104958319A (zh) | 具有卵巢早衰及围绝经期综合征治疗作用的间充质干细胞及其细胞因子制剂及其制备方法 | |
CN105769910B (zh) | 一种人羊膜间充质干细胞的应用 | |
JP2010504083A (ja) | 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用 | |
CN110013544B (zh) | 小分子组合在制备治疗慢性肝损伤的药物中的应用 | |
JP2010504083A5 (zh) | ||
WO2020030091A1 (zh) | 用于治疗组织坏死或改善心脏功能的药物 | |
CN112121042B (zh) | Pso用于制备抗败血症及其诱发的心肌损伤药物的应用 | |
CN111562394B (zh) | 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用 | |
Zhu et al. | Preliminary study on the mechanism of acupoint injection of bonemarrow mesenchymal stem cells in improving blood flow in the rat of hind limb ischemia | |
US11622964B2 (en) | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof | |
CN113559273B (zh) | 一种静脉注射用成体干细胞的预处理方法、成体干细胞注射液及应用 | |
WO2021213488A1 (zh) | 抑制细胞因子风暴的方法及组合物 | |
CN111481535B (zh) | Idhp用于制备抗败血症及其诱发的心肌损伤药物的应用 | |
CN113702645A (zh) | Sirt4在心血管疾病治疗中的用途 | |
CN105181976A (zh) | 三结构域蛋白8(trim8)抑制剂在抑制心肌肥厚中的功能及应用 | |
CN114533726B (zh) | 一种用于抑制纤维化的小分子药物及其应用 | |
CN108379246A (zh) | 莽草酸在制备预防或治疗脱髓鞘疾病药物中的应用 | |
CN110151791B (zh) | 内皮祖细胞在移植治疗大鼠冠状动脉微栓塞中的应用 | |
CN107456471B (zh) | 石榴皮在制备促进骨髓间充质干细胞迁移药物中的应用、药物及其制备方法 | |
CN114560817A (zh) | 一种用于抑制纤维化的小分子药物及其应用 | |
CN117599190A (zh) | Chchd3表达促进剂在制备心肌梗死药物中的应用 | |
CN117890602A (zh) | 抑制tnf受体相关蛋白1的医药用途 | |
CN117653730A (zh) | 二甲基丁酰基肉碱抑制剂在制备抗血栓药物中的应用 | |
CN116535459A (zh) | 一种酚酸类化合物及其合成方法、用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19847075 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3109199 Country of ref document: CA Ref document number: 2021531168 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217006661 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019318661 Country of ref document: AU Date of ref document: 20190809 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019847075 Country of ref document: EP Effective date: 20210310 |